Aviso Financial Inc. Buys 3,468 Shares of Johnson & Johnson $JNJ

Key Points

• Aviso Financial Inc. increased its stake in Johnson & Johnson by 13.3%, now holding 29,474 shares worth approximately $4.89 million.
• Johnson & Johnson's most recent earnings report showed an EPS of $2.77, surpassing estimates, with a revenue increase of 5.8% year-over-year.
• The company declared a quarterly dividend of $1.30 per share, with a yield of 2.9% and a payout ratio of 55.61%.

Aviso Financial Inc. raised its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 13.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 29,474 shares of the company's stock after buying an additional 3,468 shares during the period. Aviso Financial Inc.'s holdings in Johnson & Johnson were worth $4,888,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the business. Elios Financial Group Inc. raised its holdings in Johnson & Johnson by 1.5% in the 1st quarter. Elios Financial Group Inc. now owns 4,496 shares of the company's stock worth $746,000 after purchasing an additional 66 shares during the period. Atlantic Family Wealth LLC raised its holdings in Johnson & Johnson by 4.4% in the 1st quarter. Atlantic Family Wealth LLC now owns 1,603 shares of the company's stock worth $266,000 after purchasing an additional 67 shares during the period. MBA Advisors LLC raised its holdings in Johnson & Johnson by 1.2% in the 1st quarter. MBA Advisors LLC now owns 5,553 shares of the company's stock worth $921,000 after purchasing an additional 68 shares during the period. Sovereign Financial Group Inc. raised its holdings in Johnson & Johnson by 1.8% in the 1st quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company's stock worth $651,000 after purchasing an additional 69 shares during the period. Finally, Nabity Jensen Investment Management Inc raised its holdings in Johnson & Johnson by 1.5% in the 1st quarter. Nabity Jensen Investment Management Inc now owns 4,624 shares of the company's stock worth $767,000 after purchasing an additional 69 shares during the period. Institutional investors and hedge funds own 69.55% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on JNJ shares. Leerink Partners downgraded Johnson & Johnson from an "outperform" rating to a "market perform" rating and lowered their price objective for the company from $169.00 to $153.00 in a research report on Tuesday, May 13th. Guggenheim restated a "neutral" rating and issued a $167.00 price objective (up from $164.00) on shares of Johnson & Johnson in a research report on Thursday, July 17th. Wall Street Zen downgraded Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research report on Friday, July 18th. Barclays boosted their price objective on Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a research report on Thursday, July 17th. Finally, UBS Group boosted their price objective on Johnson & Johnson from $180.00 to $190.00 and gave the company a "buy" rating in a research report on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $174.50.

Johnson & Johnson Trading Up 0.4%

Shares of NYSE JNJ traded up $0.7890 during trading hours on Wednesday, hitting $178.5890. 9,028,878 shares of the company traded hands, compared to its average volume of 9,045,183. The stock has a market capitalization of $430.10 billion, a price-to-earnings ratio of 19.10, a price-to-earnings-growth ratio of 2.24 and a beta of 0.41. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The company's 50 day moving average price is $162.13 and its 200 day moving average price is $158.73. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $180.61.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. During the same quarter last year, the firm earned $2.82 earnings per share. The firm's quarterly revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be paid a $1.30 dividend. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 2.9%. Johnson & Johnson's dividend payout ratio (DPR) is presently 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.